UrologyNews.net

Urology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Farmaexplorer.it

Search results for "Metastatic castration-resistant prostate cancer"

The androgen receptor inhibitor, Enzalutamide ( Xtandi ) is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on Docetaxel. A study has assessed the ac ...


The results from the phase 2 TERRAIN trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in metastatic castration-resistant prostate cancer ( CRPC ) are published in the Lancet Oncol ...


Researchers aimed to identify clinical predictors of long-term response to Abiraterone [ Zytiga ] ( defined as more than 12 months drug exposure ) in a retrospective cohort of metastatic castration-re ...


The aim of a study was to evaluate the safety profile of Abiraterone acetate ( Zytiga ) in metastatic castration-resistant prostate cancer ( mCRPC ) men with cardiovascular comorbidity, as little conc ...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with androgen deprivation therapy ( ADT ), demonstrated a significant improv ...


New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San Francisco, and were simultaneously published in The New England Journal of M ...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic progression-free survival ( rPFS ) with Olaparib ( Lynparza ) in ...


The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide ( Xtandi; n = 933 ) versus placebo ( n = 468 ) in asymptomatic men wi ...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell effectors that kill tumor cells. Pu ...